{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:08:27Z","timestamp":1793207307056,"version":"4.5.0"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>There have been advances in the diagnosis and treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Themes in PMR and GCA include classification criteria, ultrasound imaging of temporal and axillary arteries replacing biopsies for diagnosis of GCA, faster diagnosis and treatment with rapid access clinics for suspected GCA, and expanding treatment options with the goal of rapid suppression of inflammation and sparing steroids.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Treatment is aimed at suppressing inflammation quickly in both GCA and PMR. Randomized trials have demonstrated success in reducing glucocorticoids when adding advanced therapies such as interleukin 6 (IL6) inhibitors. Other treatments including Janus kinase (JAK) inhibitors (especially a phase 3 trial of upadacitinib at 15\u200amg daily and secukinumab (an IL17 inhibitor) are being tested. Some uncontrolled GCA protocols are limiting glucocorticoids to initial IV pulse therapy only or rapid tapering of oral glucocorticoids with upfront treatment with tocilizumab. There is uncertainty of who should have an advanced therapy and how long to use it for and what order to consider advanced therapies when treatment fails. In PMR, studies are performed when patients cannot taper glucocorticoids effectively, whereas in GCA, advanced therapies are started with disease onset or with recurrent GCA.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000001059","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T13:00:26Z","timestamp":1728910826000},"page":"32-38","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Polymyalgia rheumatica and giant cell arteritis: diagnosis and management"],"prefix":"10.1097","volume":"37","author":[{"given":"Margaret Man-Ger","family":"Sun","sequence":"first","affiliation":[{"name":"Schulich School of Medicine & Dentistry"},{"name":"Western University"},{"name":"Department of Medicine, Division of Rheumatology, St Joseph's Healthcare, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Pope","sequence":"additional","affiliation":[{"name":"Schulich School of Medicine & Dentistry"},{"name":"Western University"},{"name":"Department of Medicine, Division of Rheumatology, St Joseph's Healthcare, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"R1-20250108","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/ard.2009.111005","article-title":"Increase in age at onset of giant cell arteritis: a population-based study","volume":"69","author":"Kermani","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R2-20250108","doi-asserted-by":"crossref","first-page":"A544","DOI":"10.1016\/j.autrev.2012.01.003","article-title":"Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment","volume":"11","author":"Borchers","year":"2012","journal-title":"Autoimmun Rev"},{"key":"R3-20250108","doi-asserted-by":"crossref","first-page":"102670","DOI":"10.1016\/j.autrev.2020.102670","article-title":"The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle","volume":"19","author":"Carvajal Alegria","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R4-20250108","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of giant cell arteritis and takayasu arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R5-20250108","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1056\/NEJMcp1214825","article-title":"Giant-cell arteritis and polymyalgia rheumatica","volume":"371","author":"Weyand","year":"2014","journal-title":"N Engl J Med"},{"key":"R6-20250108","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol"},{"key":"R7-20250108","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/art.24459","article-title":"Epidemiology of giant cell arteritis and polymyalgia rheumatica","volume":"61","author":"Gonzalez-Gay","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R8-20250108","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.semarthrit.2003.09.007","article-title":"Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions","volume":"33","author":"Gonzalez-Gay","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"R9-20250108","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia rheumatica and giant cell arteritis: a systematic review","volume":"315","author":"Buttgereit","year":"2016","journal-title":"JAMA"},{"key":"R10-20250108","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.3390\/jcm11247412","article-title":"Predictive factors of giant cell arteritis in polymyalgia rheumatica patients","volume":"11","author":"Ramon","year":"2022","journal-title":"J Clin Med"},{"key":"R11-20250108","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MD.0b013e318145275c","article-title":"Development of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica: study of a series of 100 patients","volume":"86","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2007","journal-title":"Medicine"},{"key":"R12-20250108","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3899\/jrheum.170455","article-title":"Development of giant cell arteritis after treating polymyalgia or peripheral arthritis: a retrospective case-control study","volume":"45","author":"Liozon","year":"2018","journal-title":"J Rheumatol"},{"key":"R13-20250108","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.semarthrit.2015.06.009","article-title":"Prevalence of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica","volume":"45","author":"Narv\u00e1ez","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"R14-20250108","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/ard.2003.011692","article-title":"Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: a quantitative PET study","volume":"63","author":"Moosig","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"R15-20250108","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/acr2.11163","article-title":"The utility of 18F-FDG PET\/CT in patients with clinical suspicion of polymyalgia rheumatica and giant cell arteritis: a prospective, observational, and cross-sectional study","volume":"2","author":"Emamifar","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"R16-20250108","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3109\/s10165-011-0581-x","article-title":"Whole-body fluorodeoxyglucose positron emission tomography\/computed tomography in patients with active polymyalgia rheumatica: evidence for distinctive bursitis and large-vessel vasculitis","volume":"22","author":"Yamashita","year":"2012","journal-title":"Mod Rheumatol"},{"issue":"(Suppl 1)","key":"R17-20250108","first-page":"438","article-title":"POS0415 sonographic prevalence and characteristics of subclinical giant cell arteritis in new onset polymyalgia rheumatica","volume":"83","author":"Abu-Zaid","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R18-20250108","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/ard-2023-224768","article-title":"Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica","volume":"83","author":"De Miguel","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl 1)","key":"R19-20250108","first-page":"440","article-title":"POS0431 baseline vascular ultrasound of PMR patients at time of diagnosis stratifies relapse risk at 6 months","volume":"83","author":"Cowley","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R20-20250108","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/rheumatology\/keaa646","article-title":"New insights into the role of imaging in polymyalgia rheumatica","volume":"60","author":"Camellino","year":"2021","journal-title":"Rheumatology"},{"key":"R21-20250108","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1136\/ard-2022-223480","article-title":"2022 American College of Rheumatology\/EULAR classification criteria for giant cell arteritis","volume":"81","author":"Ponte","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R22-20250108","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/art.34356","article-title":"2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"64","author":"Dasgupta","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R23-20250108","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","article-title":"2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"71","author":"Dasgupta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R24-20250108","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/acr.24393","article-title":"Association between specimen length and number of sections and diagnostic yield of temporal artery biopsy for giant cell arteritis","volume":"73","author":"Muratore","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R25-20250108","article-title":"Halo sign on temporal artery ultrasound versus temporal artery biopsy for giant cell arteritis","volume":"2024","author":"Pouncey","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"R26-20250108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20900","article-title":"The role of ultrasound compared to biopsy of temporal arteries in the diagnosis and treatment of giant cell arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study","volume":"20","author":"Luqmani","year":"2016","journal-title":"Health Technol Assess"},{"key":"R27-20250108","doi-asserted-by":"crossref","first-page":"729","DOI":"10.7326\/M23-3417","article-title":"Diagnostic strategy using color doppler ultrasound of temporal arteries in patients with high clinical suspicion of giant cell arteritis: a prospective cohort study","volume":"177","author":"Denis","year":"2024","journal-title":"Ann Intern Med"},{"key":"R28-20250108","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R29-20250108","doi-asserted-by":"crossref","first-page":"981659","DOI":"10.3389\/fmed.2022.981659","article-title":"Evolution of ultrasound in giant cell arteritis","volume":"9","author":"Kirby","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R30-20250108","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"R31-20250108","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R32-20250108","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.39333","article-title":"2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology Collaborative Initiative","volume":"67","author":"Dejaco","year":"2015","journal-title":"Arthritis and Rheumatology"},{"key":"R33-20250108","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/acr.25216","article-title":"Treatment of polymyalgia rheumatica by rheumatology providers: analysis from the American College of Rheumatology RISE Registry","volume":"76","author":"Sattui","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"(Suppl 1)","key":"R34-20250108","first-page":"438","article-title":"POS0411 characteristics at diagnosis associated to glucocorticoid use at 2 years for those with polymyalgia rheumatica \u2212 a national study of England","volume":"83","author":"Yates","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R35-20250108","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"key":"R36-20250108","doi-asserted-by":"crossref","first-page":"e619","DOI":"10.1016\/S2665-9913(21)00152-1","article-title":"Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study","volume":"3","author":"Christ","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"R38-20250108","doi-asserted-by":"crossref","first-page":"e736","DOI":"10.1016\/S2665-9913(23)00265-5","article-title":"Treatment for giant cell arteritis with 8\u200aweeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study","volume":"5","author":"Unizony","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"R39-20250108","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.semarthrit.2021.03.006","article-title":"Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial","volume":"51","author":"Spiera","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"R40-20250108","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jama.2022.15459","article-title":"Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial","volume":"328","author":"Devauchelle-Pensec","year":"2022","journal-title":"JAMA"},{"key":"R41-20250108","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","article-title":"Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial","volume":"81","author":"Bonelli","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R42-20250108","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJMoa2303452","article-title":"Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper","volume":"389","author":"Spiera","year":"2023","journal-title":"N Engl J Med"},{"key":"R43-20250108","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13075-023-03177-6","article-title":"A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis","volume":"25","author":"Schmidt","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"(Suppl 1)","key":"R44-20250108","first-page":"232","article-title":"LBA0001 efficacy and safety of upadacitinib in patients with giant cell arteritis (Select-GCA): a double-blind, randomized controlled phase 3 trial","volume":"83","author":"Blockmans","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R45-20250108","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/annrheumdis-2021-221961","article-title":"Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study","volume":"81","author":"Koster","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R46-20250108","doi-asserted-by":"crossref","first-page":"e1004249","DOI":"10.1371\/journal.pmed.1004249","article-title":"Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica (EAST PMR): an open-label randomized controlled trial","volume":"20","author":"Ma","year":"2023","journal-title":"PLoS Med"},{"key":"R47-20250108","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/ard-2022-223562","article-title":"Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: a phase 2 study","volume":"82","author":"Zhang","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R48-20250108","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2665-9913(23)00101-7","article-title":"Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Venhoff","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"R49-20250108","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.1016\/S2665-9913(21)00245-9","article-title":"Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial","volume":"3","author":"Marsman","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"R50-20250108","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(23)00032-2","article-title":"1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial","volume":"5","author":"Bolhuis","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"R51-20250108","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/rheumatology\/keab280","article-title":"Steroid-sparing effect of anakinra in giant-cell arteritis: a case series with clinical, biological and iconographic long-term assessments","volume":"61","author":"Deshayes","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R52-20250108","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"},{"key":"R53-20250108","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","article-title":"Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial","volume":"73","author":"Seror","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R54-20250108","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/ard.2007.082115","article-title":"A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects","volume":"67","author":"Mart\u00ednez-Taboada","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R55-20250108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar3140","article-title":"Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial","volume":"12","author":"Kreiner","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"R56-20250108","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1136\/annrheumdis-2016-209351","article-title":"Ustekinumab for the treatment of refractory giant cell arteritis","volume":"75","author":"Conway","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R57-20250108","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/acr.24200","article-title":"Ustekinumab for the treatment of giant cell arteritis","volume":"73","author":"Matza","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R58-20250108","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R59-20250108","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.1016\/S2665-9913(23)00246-1","article-title":"Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial","volume":"5","author":"Saraux","year":"2023","journal-title":"Lancet Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T11:07:27Z","timestamp":1736334447000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001059","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,14]]}}}